Navigation Links
UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis
Date:10/17/2009

PHILADELPHIA, Oct. 17 /PRNewswire/ -- UCB today announced data that showed rapid and sustained improvements in ACR20, physical function, pain and fatigue of rheumatoid arthritis (RA) as early as the first week, and inhibition of progression of structural joint damage (seen at week 24) following treatment with Cimzia® (certolizumab pegol), together with methotrexate (MTX), was sustained up to 100 weeks. Cimzia® is approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis. Cimzia® can be dosed at 400 mg initially and at weeks 2 and 4, followed by 200 mg every other week; for maintenance dosing, 400 mg every 4 weeks can be considered.

Also presented at the Annual Scientific Meeting of the American College of Rheumatology (ACR) in Philadelphia data from a post hoc analysis() showed the speed of developing a clinical response to treatment with 200 mg Cimzia® and MTX, was important in improving long-term outcomes for patients living with active RA. The analysis found most patients achieved early control at Week 6. These patients had significantly better control of symptoms and significantly better improvements in pain and physical function at one year, compared to patients who achieved a later response at Week 12.

"These recently published data have shown Cimzia® to work rapidly, and demonstrate that an early response to treatment is associated with greater improvements in long-term outcomes," said lead investigator Edward Keystone, M.D., at The Rebecca MacDonald Center for Arthritis, Mount Sinai Hospital, The University of Toronto. "The data also confirm the rapid and sustained effect of Cimzia® in providing effective and clinically meaningful relief of rheumatoid arthritis, and reducing disease progression," he added. "This highlights the importance of getting the disease under control quickly in this debilitating condition which helps improve overall quality of l
'/>"/>

SOURCE UCB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohns Patients
2. New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohns Patients With Fistulizing Disease
3. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
4. Tiny test tube experiment shows reaction of melting materials at the nano scale
5. New Survey Shows Devastating Impact of Rheumatoid Arthritis Pain on Intimate Relations
6. Topical erectile dysfunction therapy shows promise
7. Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost
8. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
9. Video shows nanotube spins as it grows
10. MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients
11. Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 WriteResult, LLC – a premier ... again shown superiority when it comes to meeting the ... ePRO portion of their most recent study closeout on-time ... chose WriteResult’s digital writing platform to collect Patient Reported ... to complete drew data from a number of assessments ...
(Date:8/26/2014)... , Aug. 26, 2014  NeuroSigma, Inc., a ... established to develop bioelectronic technologies, today announced that it ... the U.S. Securities and Exchange Commission relating to a ... number of shares to be offered and the price ... determined. Jefferies LLC will act as the ...
(Date:8/26/2014)... 2014 The 20 ambassadors representing the ... community issued the following statement on Facebook today regarding ... driving new funding specifically for ALS research: , “Who ... some ice would raise all this awareness and funding ... and on behalf of the entire ALS community, would ...
(Date:8/26/2014)... REHOVOT, Israel , August 26, 2014 /PRNewswire/ ... specialist, Replica 3DM, supports NHS hospitals with surgery validation using ... - Performing surgery on 3D printed models ... patient recovery and provides an effective aid for both patient ... (Nasdaq: SSYS ), a global leader of 3D ...
Breaking Biology Technology:A Perfect Record: WriteResult Maintains a 100% On-Time ePRO Record with Latest Irritable Bowel (IBS) Study Data Lock 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 3ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 2Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 3Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 5
... DIEGO, April 9, 2008 ADVENTRX,Pharmaceuticals, Inc. (Amex: ... appointed,Jose Hechavarria to the new position of vice ... leading the company,s planned,commercial manufacturing operations., "We ... team," said Evan M.,Levine, ADVENTRX chief executive officer. ...
... future ... sales ... LOR; AMEX: LRP), a biopharmaceutical company dedicated to,the research and development ... that its subsidiary GeneSense,Technologies, Inc. ("GeneSense") has signed an exclusive multinational,license ...
... Inc. (Nasdaq: TPPH ) today announced that ... Market ("Nasdaq") formally notifying it that,Nasdaq has not ... January,2, 2008, as required by Marketplace Rule 4310(c)(14) ... will be suspended. Tapestry,does not intend to appeal ...
Cached Biology Technology:ADVENTRX Appoints Vice President of Manufacturing 2ADVENTRX Appoints Vice President of Manufacturing 3Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R) 2Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R) 3Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R) 4Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R) 5Tapestry Receives Nasdaq Delisting Notice 2
(Date:8/27/2014)... evidence puts into doubt the long-standing belief that a ... brain plays a central role in depression. In ... that mice lacking the ability to make serotonin in ... conventional wisdom) did not show depression-like symptoms. , ... VA Medical Center and Wayne State University School of ...
(Date:8/27/2014)... number of studies have shown that excessive ... of Parkinson,s disease. Previous studies from Chunyan ... in China have shown that baicalin prevented ... divalent metal transporter 1 expression, and increased ... of rotenone-induced Parkinson,s disease rats. However, the ...
(Date:8/27/2014)... Listeria is a dreaded bacterium that can be ... last few weeks, 28 persons in Denmark have been ... in supermarkets. 13 have died. , The bacterium is ... uncanny ability to adapt to changes in its surroundings, ... Together with colleagues from the Department of Biochemistry and ...
Breaking Biology News(10 mins):New study throws into question long-held belief about depression 2Researchers discover why Listeria bacterium is so hard to fight 2Researchers discover why Listeria bacterium is so hard to fight 3
... SAN DIEGO , May 11 ... Biomatrica Connect™, a solution-centric partnership program established with ... room temperature storage and management of nucleic acids. ... scientific/industry partnership for the development, testing, validation and ...
... commentary on the nature of pathogens is raising startling new ... plays in the understanding of emerging disease. Ecological speciation, and ... shifts onto a novel host, is one of the main ... argue the authors of a new paper published online in ...
... NY) A multi-institutional team of researchers, including scientists ... has received a prestigious National Institutes of Health (NIH) ... structure and function of unknown enzymes identified in genome-sequencing ... the metabolic and chemical diversity that exists in nature ...
Cached Biology News:Biomatrica Launches New Partnership Program - Biomatrica Connect(TM) 2Biomatrica Launches New Partnership Program - Biomatrica Connect(TM) 3Biomatrica Launches New Partnership Program - Biomatrica Connect(TM) 4Biomatrica Launches New Partnership Program - Biomatrica Connect(TM) 5Biomatrica Launches New Partnership Program - Biomatrica Connect(TM) 6Emergence of fungal plant diseases linked to ecological speciation 2NIH funds multicenter 'glue grant' to study enzyme function 2
... were designed for full-length gene cloning and ... identify the desired cDNA clone. The first ... "Master Plate," where each well contains plasmid ... positive well(s) by gel electrophoresis of the ...
... Panels were designed for full-length gene cloning ... to identify the desired cDNA clone. The ... 96-well "Master Plate," where each well contains ... the positive well(s) by gel electrophoresis of ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
... With the macro- and micronutrients ... Skoog (1962) and the vitamins ... al. (1968). Preparation Quantity Equivalency: ... of powder per liter of ...
Biology Products: